Introduction
Accretion/dilution analysis is one of the most important and most heavily tested M&A concepts in investment banking. It answers a specific question that every acquiring company's board and shareholders care about: will this deal increase or decrease our earnings per share? A deal where the combined EPS exceeds the acquirer's standalone EPS is accretive (positive for existing shareholders). A deal where the combined EPS falls below standalone EPS is dilutive (negative for existing shareholders in the near term).
This analysis does not determine whether a deal is "good" or "bad" (a strategically transformative deal may be dilutive in Year 1 but massively accretive by Year 3). But it is a critical data point that influences deal approval, form of consideration, and the public narrative around the transaction. For a detailed walkthrough with examples, see our blog post on accretion/dilution analysis.
The Core Framework
The analysis builds the pro forma combined EPS and compares it to the acquirer's standalone EPS:
If the result is positive, the deal is accretive. If negative, it is dilutive. The percentage accretion/dilution is:
Building the Pro Forma EPS
Step 1: Start with the Acquirer's Standalone Net Income
The acquirer's net income before the transaction, using the most recent LTM or consensus NTM estimate.
Step 2: Add the Target's Net Income
The target's net income represents the earnings contribution from the acquired business. This is the primary source of accretion: the target's earnings "flow up" to the combined entity.
Step 3: Subtract the Financing Costs
The cost of funding the acquisition reduces the combined net income. The specific adjustment depends on the form of consideration:
- Cash consideration: The acquirer uses cash on hand to fund the purchase. The foregone interest income on that cash (net of tax) is a cost. If the acquirer uses $1 billion in cash that was earning 4% pre-tax, the after-tax cost is $1B x 4% x (1-25%) = $30 million reduction in net income.
- Debt consideration: The acquirer borrows to fund the purchase. The after-tax interest expense on new debt is the cost. $1 billion borrowed at 6% with a 25% tax rate costs $1B x 6% x (1-25%) = $45 million annually.
- Stock consideration: The acquirer issues new shares. There is no explicit financing cost, but the share count increases, diluting EPS. The "cost" of stock is implicit in the additional shares in the denominator.
Step 4: Apply Transaction Adjustments
- Amortization of acquired intangibles: The purchase price allocation creates new intangible assets (customer relationships, technology, trade names) that are amortized over their useful lives. This non-cash amortization reduces pre-tax income, net of the tax benefit.
- Elimination of inter-company items: Any revenue or expenses between the two companies that will not exist post-merger.
Step 5: Add Synergies (If Included)
After-tax cost synergies and revenue synergies increase the combined net income. Whether synergies are included in the base case or shown separately as a sensitivity is a judgment call that depends on the certainty of the synergies and the bank's convention.
Step 6: Calculate Pro Forma Shares Outstanding
- If cash deal: Pro forma shares = acquirer's current diluted shares (no change)
- If stock deal: Pro forma shares = acquirer's shares + new shares issued to target shareholders
- If mixed: Adjust for the stock portion
Step 7: Calculate Pro Forma EPS
- Accretion/Dilution
An analysis that measures whether an M&A transaction increases (accretion) or decreases (dilution) the acquirer's earnings per share (EPS). A deal is accretive when the target's earnings contribution, net of financing costs and transaction adjustments, increases the pro forma combined EPS above the acquirer's standalone EPS. A deal is dilutive when the financing costs and adjustments exceed the target's earnings contribution. Accretion/dilution is one of the most frequently tested M&A concepts in investment banking interviews.
How the Form of Consideration Changes the Analysis
The form of consideration is the single most impactful variable in accretion/dilution analysis because it determines both the cost side (what the acquirer gives up to fund the deal) and the share count (the denominator of the EPS calculation).
All-Cash Deal
In a cash deal, the acquirer either uses cash on its balance sheet or borrows to fund the purchase. The EPS impact depends on whether the target's earnings contribution exceeds the financing cost:
If the target earns $100 million and the after-tax cost of the cash used (foregone interest or new debt interest) is $75 million, the deal adds $25 million to the combined net income. Since no new shares are issued, this $25 million flows directly to a higher EPS.
Cash deals are generally more accretive than stock deals in high-interest-rate environments because the cost of cash (foregone interest at 4-5%) is lower than the implicit cost of stock (the acquirer's earnings yield, which may be 5-8%). However, cash deals consume balance sheet resources, which may limit future flexibility.
All-Stock Deal
In a stock deal, the acquirer issues new shares to the target's shareholders. There is no cash financing cost, but the share count increases, diluting existing shareholders. The accretion/dilution outcome depends entirely on the relative P/E ratios of the two companies.
- P/E Arbitrage (in Stock-for-Stock Deals)
The mechanical effect where a higher-P/E acquirer can increase its EPS by acquiring a lower-P/E target using stock. The acquirer issues shares worth less in "earnings terms" than the earnings it receives from the target. For example, if the acquirer trades at 20x P/E and the target at 12x, each dollar of target earnings costs the acquirer only $0.60 of its own earnings (12/20), making the deal immediately accretive. The reverse creates dilution: a 12x acquirer buying a 20x target gives up more earnings-equivalent shares than it receives. This mechanical effect is independent of whether the deal is strategically sound.
Mixed Consideration
Most large M&A transactions use a combination of cash and stock. The accretion/dilution analysis must calculate the financing cost on the cash portion and the share count increase on the stock portion separately, then combine. The mix can be optimized: if the deal is dilutive at 100% stock, shifting to 50% cash / 50% stock may make it accretive (if the cash financing cost is lower than the implied stock cost).
This optimization dynamic is one reason form of consideration analysis is a core part of the merger model. The banker runs the accretion/dilution at multiple mix ratios (100% cash, 75/25, 50/50, 25/75, 100% stock) and presents the results to the board, showing which mix produces the most favorable EPS outcome.
The Quick Rule of Thumb: Earnings Yield vs. Cost of Funding
For a rapid assessment of whether a deal is likely accretive or dilutive, compare the target's earnings yield (net income / purchase price) to the acquirer's cost of funding:
- Cash deal: Compare target's earnings yield to the acquirer's after-tax return on cash. If the target yields more than the cash was earning, the deal is accretive.
- Debt deal: Compare target's earnings yield to the after-tax cost of new debt. If the target yields more than the debt costs, the deal is accretive.
- Stock deal: Compare target's P/E to the acquirer's P/E. If the acquirer's P/E is higher than the target's P/E, the deal is accretive (the acquirer is using "expensive" currency to buy "cheap" earnings). If the acquirer's P/E is lower, the deal is dilutive.
Why Accretion/Dilution Matters (and Why It Has Limits)
Why It Matters
Boards, shareholders, and equity research analysts scrutinize accretion/dilution because EPS is the metric most directly connected to stock price performance. A dilutive deal may trigger a negative stock price reaction, and boards are reluctant to approve transactions that will reduce near-term EPS, even if the strategic rationale is compelling.
Why It Has Limits
Accretion/dilution is a near-term, accounting-driven metric that does not capture the full economic value of a transaction:
- A deal may be dilutive in Year 1 (before synergies are realized) but accretive in Year 2-3 (after integration is complete). Presenting only the Year 1 impact is misleading.
- Accretion/dilution does not account for the strategic value of the acquisition: market positioning, competitive dynamics, technology capabilities, or long-term growth potential.
- The analysis is heavily influenced by the form of consideration: the same deal can be accretive if funded with cash and dilutive if funded with stock, even though the economic value of the acquisition has not changed.
- Non-cash charges like PPA amortization reduce EPS but do not affect cash flow, meaning a deal can be dilutive on an accounting basis while generating significant cash accretion. Some companies and analysts use cash EPS (excluding non-cash amortization) as a supplementary metric to avoid penalizing deals with large intangible asset step-ups.
When Boards Accept Dilution
Despite the scrutiny around accretion/dilution, many boards approve dilutive transactions when the strategic rationale is compelling. The key factors that justify accepting near-term dilution include:
Accretive by Year 2-3: If the deal is 2-3% dilutive in Year 1 but 5-10% accretive by Year 3 (after synergies), the board may view the short-term dilution as an acceptable cost of long-term value creation. The multi-year trajectory is presented prominently to support this argument.
Transformative strategic value: Deals that fundamentally reposition the company (entering a new market, acquiring a disruptive technology, consolidating a fragmented industry) may justify dilution because the strategic benefits are not captured in the EPS math. Microsoft's $69 billion acquisition of Activision Blizzard was initially dilutive to EPS but gave Microsoft a dominant position in gaming content for its Xbox and cloud platforms.
Revenue growth acceleration: A high-growth acquirer buying a faster-growing target may accept dilution because the target accelerates the combined entity's revenue growth trajectory, which the market may reward with a higher multiple (offsetting the lower EPS through a higher P/E).
The communication to shareholders is critical. Companies announcing dilutive transactions typically emphasize the timeline to accretion ("accretive within 24 months"), the synergy commitments ("$X in annual cost synergies by Year 3"), and the strategic rationale ("positions us as the #1 player in [market]"). If the market is unconvinced, the acquirer's stock price drops on announcement, which is a de facto vote on whether the dilution is acceptable.
Multi-Year Accretion/Dilution: The Year 1-3 Trajectory
A complete accretion/dilution analysis shows the EPS impact over multiple years (typically Years 1-3), not just the first year. This multi-year view is essential because many deals that are dilutive in Year 1 become accretive by Year 2 or 3 as synergies phase in and the target's growth contributes to combined earnings.
The trajectory depends on three factors:
Synergy phasing: If cost synergies are phased 30% / 70% / 100% over 3 years, the deal becomes progressively more accretive each year as more synergy value is realized. A deal that is 3% dilutive in Year 1 (before synergies) may be 2% accretive in Year 2 (with partial synergies) and 8% accretive in Year 3 (with full synergies).
Target growth: If the target is growing faster than the acquirer, its earnings contribution increases each year, making the deal more accretive over time. This is particularly important for growth acquisitions where the target's current earnings understate its future potential.
PPA amortization wind-down: The amortization of acquired intangible assets (purchase price allocation) is a non-cash charge that reduces Year 1 EPS. As the shorter-lived intangibles are fully amortized (customer relationships may have 5-7 year lives, trade names may have 10-15 years), this drag decreases over time.
Sensitivity Analysis
The accretion/dilution output should be presented as a sensitivity table showing how the result changes across different assumptions:
| Variable | Impact on Accretion/Dilution |
|---|---|
| Higher purchase price | More dilutive (higher financing cost for same earnings) |
| More synergies | More accretive (higher combined net income) |
| Cash vs. stock mix | Cash is cheaper (foregone interest < stock dilution) at current rates |
| Higher target growth | More accretive over time (Year 2-3 improvement) |
| Higher interest rates | Cash/debt-funded deals more dilutive (higher financing cost) |
The most common sensitivity table shows accretion/dilution across a grid of purchase price premium vs. synergy realization rate, showing the breakeven point where the deal shifts from accretive to dilutive.
A second common sensitivity shows the accretion/dilution at different consideration mixes (100% cash through 100% stock), allowing the board to see how the financing structure affects the EPS outcome. This analysis often reveals that an all-stock deal is dilutive while a 50/50 cash-stock mix is accretive, directly influencing the board's decision on how to structure the offer.
How Accretion/Dilution Is Presented to the Board
In a buy-side advisory context, the accretion/dilution analysis is typically presented as a one-page summary showing:
Headline result: "The transaction is X% accretive/(dilutive) to EPS in Year 1 and Y% accretive by Year 3, assuming full synergy realization." This single sentence is what the board remembers and what appears in the press release.
Sensitivity grid: A table showing accretion/dilution across a range of purchase prices and synergy realization rates, making it clear where the breakeven sits and how much margin of safety exists.
Year 1-3 trajectory: A line chart or table showing how the EPS impact evolves as synergies phase in and PPA amortization declines. This multi-year view is critical because boards need to understand the path from potential Year 1 dilution to Year 3 accretion.
Consideration mix comparison: A side-by-side showing the accretion/dilution at different cash/stock mixes (100% cash, 50/50, 100% stock), informing the board's decision on how to structure the offer.
The sell-side banker presents a mirror-image version to the target's board: showing that the offered premium is justified by the synergy value and that the deal structure provides fair value to the target's shareholders. In a fairness opinion, both the acquirer's and target's advisors include accretion/dilution analysis as one component of the financial assessment, though it is not the sole determinant of fairness.
Free Interview PDF Guide